Sanofi announced the successful completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, a privately held, clinical-stage biopharmaceutical...
Dren Bio, Inc, a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, announced that it has entered...
